Home > Products

Products

You can also try the following methods, and our professionals will serve you Customized Consultation
Cat. No. Product Name Field of Application Chemical Structure
DCC4859 Spla2 Inhibitor Pyr-1 Novel potent sPLA2 inhibitor, selectively targeting hGIIA and hGIID
DCC4860 Spmtrien Novel isosteric charge-deficient spermine analogue
DCC4861 spongiacidin C USP7 inhibitor from the marine sponge Stylissa massa
DCC4862 Spongosine Pivotal intercellular signal transmitter
DCC4863 Spop-in-6lc Novel SPOP inhibitor, suppressing the viability and inhibiting the colony formation of ccRCC cell lines driven by cytoplasmic SPOP
DCC4864 Spt-in-1 Novel potent serine palmitoyl transferase (SPT) inhibitor
DCC4865 Sptssb-binder-18 Novel potent and selective binder of small subunit B of the serine palmitoyltransferase complex (SPTSSB)
DCC4866 Spu-106 Novel specific PAK4 inhibitor, effectively inhibiting the invasion of SGC7901 cells without cytotoxicity, regulating the PAK4/LIMK1/cofilin and PAK4/SCG10 signaling pathways
DCC4867 Sr-01000634273-1 Novel inhibitor of the in vivo aggregation of
DCC4868 Sr10098 Novel NR4A nuclear receptor modulator
DCC4869 Sr10658 Novel NR4A nuclear receptor modulator
DCC4870 Sr142948a Selective neurotensin antagonist
DCC4871 Sr-17398 Hydrochloride Novel Unc-51-Like Kinase 1 (ULK1)
DCC4872 Sr2067 Novel partial agonist of PPARgamma
DCC4873 Sr24237 Novel NR4A nuclear receptor modulator
DCC4874 Sr-3737 Potent inhibitor of both JNK3 and p38
DCC4875 Sr-4326 Novel Inhibitor of c-Jun N-terminal Kinase 3 (JNK3)
DCC4876 Sr-43845 Novel renin inhibitor
DCC4877 Sr-58611a The first selective β3 adrenergic agonist, showing to possess a profile of antidepressant activity in rodents
DCC4878 Sr8185 Novel Selective TBK1/IKK dual inhibitor with anticancer potency
DCC4879 Srctide Peptide substrate for many protein kinases, such as Blk, BTK, cKit, EPHA1, EPHB2, EPHB3, ERBB4, FAK, Flt3, IGF-1R, ITK, Lck, MET, MUSK, Ret, Src, TIE2, TrkB, VEGF-R1 (Flt-1) and VEGF-R2 (KDR)
DCC4880 Srebp-in-dhg Novel inhibitor of sterol regulatory element-binding protein (SREBP), impairing the SREBP activity by inhibiting glucose transporters and thereby activating AMP-activated protein kinase (AMPK)
DCC4881 Sri-22138 Novel mixed μ opioid receptor (MOR) agonist and δ/κ opioid receptor (DOR/KOR) antagonist
DCC4882 Sri-29132 Highly blood-brain barrier permeant, potent, and selective for LRRK2 kinase activity, being effective in attenuating pro-inflammatory responses in macrophages and rescuing neurite retraction phenotypes in neurons.
DCC4883 Sri-31040 Potent DAT allosteric modulator, partially inhibiting DAT uptake without altering DAT-mediated reverse transport and with minimal inhibition of DAT binding
DCC4884 Sri-35241 Novel inhibitor of thrombospondin 1 activation of TGF-β, blocking TGF-β activation (pIC50 = 8.12 nM) and has a plasma half life of 1.8 h (iv)
DCC4885 Sri-36160 Novel potent inhibitor of Wn/ß-catenin signaling in cancer cells
DCC4886 Sri-37683 Novel GLUT inhibitor, preferentially inhibiting the growth of GBM cells with minimal toxicity to non-neoplastic astrocytes and neurons, also inhibiting glucose uptake and decrease the glycolytic capacity and glycolytic reserve capacity of GBM patient-deri
DCC4887 Sri-37684 Novel GLUT inhibitor, preferentially inhibiting the growth of GBM cells with minimal toxicity to non-neoplastic astrocytes and neurons, also inhibiting glucose uptake and decrease the glycolytic capacity and glycolytic reserve capacity of GBM patient-deri
DCC4888 Sri-39067 Novel MOR agonist/DOR antagonist that produced systemically active potent antinociceptive activity in tail-flick assay in mice

Customized Consultation X

Your information is safe with us. * Required Fields.

Your name
Company
Email
Procuct Name
Cat. No.
Remark
Verification code
Please fill out the characters in the picture
X